Lilly (LLY.US) reaches agreement with Camurus to jointly develop treatments for obesity and diabetes.

Wisdom Financial APP learned that Lilly (LLY.US) has signed a licensing and development agreement with Camurus. The two parties will jointly develop long-acting insulin-promoting drugs for the treatment of obesity, diabetes, and other metabolic diseases based on Camurus' FluidCrystal technology.